ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Bone Therapeutics Sa

Bone Therapeutics Sa (0R55)

3.845
0.00
(0.00%)
Closed April 28 11:30AM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
3.845
Bid
3.75
Ask
3.94
Volume
4,079
0.00 Day's Range 0.00
3.845 52 Week Range 3.845
Market Cap
Previous Close
3.845
Open
-
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
8,943
Shares Outstanding
121,897,000
Dividend Yield
-
PE Ratio
-1.19
Earnings Per Share (EPS)
-0.02
Revenue
316k
Net Profit
-2.04M

About Bone Therapeutics Sa

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Mont-saint-guibert, Walloon Brabant, Bel
Founded
1970
Bone Therapeutics Sa is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker 0R55. The last closing price for Bone Therapeutics was 3.85 €. Over the last year, Bone Therapeutics shares have traded in a share price range of 3.845 € to 3.845 €.

Bone Therapeutics currently has 121,897,000 shares outstanding. The market capitalization of Bone Therapeutics is 2.44 € million. Bone Therapeutics has a price to earnings ratio (PE ratio) of -1.19.

0R55 Latest News

BioSenic publie sur son site web le plan de restructuration soumis au tribunal des entreprises de Nivelles  

BioSenic publie sur son site web le plan de restructuration soumis au tribunal des entreprises de Nivelles   COMMUNIQUE DE PRESSE – INFORMATION PRIVILIGIEE  Mont-Saint-Guibert, Belgique, le...

BioSenic postpones its annual general meeting of the shareholders and provides temporary non-audited financial figures for 2023

BioSenic postpones its annual general meeting of the shareholders and provides temporary non-audited financial figures for 2023 PRESS RELEASE - PRIVILEGED INFORMATION In view of the...

BioSenic S.A. : Notifications de transparence reçues de la part de François Rieger

BioSenic S.A. : Notifications de transparence reçues de la part de François Rieger   COMMUNIQUE DE PRESSE – INFORMATION REGLEMENTEE Article 14 de la loi du 2 mai 2007 relative à la publicité...

BioSenic fournit des informations complémentaires sur son plan de restructuration

BioSenic fournit des informations complémentaires sur son plan de restructuration COMMUNIQUE DE PRESSE – INFORMATION PRIVILEGIEE Mont-Saint-Guibert, Belgique, le 12 avril 2024 à 12h00 CET –...

BioSenic et son praticien de la restructuration (Me Yves Brulard) soumettent un plan de restructuration global engageant les années 2024-2030 au Tribunal de l’entreprise de Nivelles

BioSenic et son praticien de la restructuration (Me Yves Brulard) soumettent un plan de restructuration global engageant les années 2024-2030 au Tribunal de l’entreprise de Nivelles...

BioSenic S.A. : Information on the total number of voting rights and shares

BioSenic S.A. : Information on the total number of voting rights and shares PRESS RELEASE – REGULATED INFORMATION Mont-Saint-Guibert, Belgium, March 29, 2024, 7.00 am CEST – BIOSENIC...

BioSenic presents successful preclinical data on its ATO medication for controlling key symptoms at the 2024 Systemic Sclerosis World Congress

BioSenic presents successful preclinical data on its ATO medication for controlling key symptoms at the 2024 Systemic Sclerosis World Congress PRESS RELEASE Preclinical data in a transgenic mouse...

BioSenic présente des données précliniques concluantes sur son médicament ATO pour le contrôle des principaux symptômes au Congrès mondial 2024 sur la sclérose systémique

BioSenic présente des données précliniques concluantes sur son médicament ATO pour le contrôle des principaux symptômes au Congrès mondial 2024 sur la sclérose systémique COMMUNIQUE DE PRESSE Des...

BioSenic publie les détails de la stratégie d'administration optimisée pour OATO dans le traitement de la maladie chronique du greffon contre l'hôte en amont du prochain essai de phase 3

BioSenic publie les détails de la stratégie d'administration optimisée pour OATO dans le traitement de la maladie chronique du greffon contre l'hôte en amont du prochain essai de phase 3...

BioSenic releases details of optimized administration approach ahead of planned Phase 3 trial of OATO for chronic graft-versus-host disease

BioSenic releases details of optimized administration approach ahead of planned Phase 3 trial of OATO for chronic graft-versus-host disease INSIDE INFORMATION New data builds on earlier findings...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1003.8453.8453.84589853.845DE
4003.8453.8453.84535573.845DE
12003.8453.8453.84589433.845DE
26003.8453.8453.845119193.845DE
52003.8453.8453.845237343.845DE
156003.8453.8453.845114673.845DE
260003.8453.8453.845112583.845DE

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BDRXBiodexa Pharmaceuticals PLC
$ 1.3254
(82.86%)
70.82M
IBRXImmunityBio Inc
$ 7.35
(43.84%)
40.28M
AGENAgenus Inc
$ 11.685
(40.78%)
3.37M
ULHUniversal Logistics Holdings Inc
$ 45.63
(38.74%)
484.22k
NIVFNewGenIvf Group Ltd
$ 1.77
(36.15%)
57.78M
MFImF International Ltd
$ 2.3153
(-77.82%)
21.23M
NWGLNature Wood Group Ltd
$ 5.05
(-70.03%)
2.48M
ICLKiClick Interactive Asia Group Ltd
$ 1.21
(-52.17%)
719.95k
NUWENewellis Inc
$ 0.1695
(-41.35%)
18.46M
SGBXSafe and Green Holdings Corporation
$ 0.1469
(-32.92%)
8.39M
PEGYPineapple Energy Inc
$ 0.065499
(26.20%)
325.57M
SQQQProShares UltraPro Short QQQ
$ 11.43
(-4.75%)
137.28M
INTCIntel Corporation
$ 31.88
(-9.20%)
119.84M
TSLATesla Inc
$ 168.29
(-1.11%)
109.84M
SOFISoFi Technologies Inc
$ 7.87
(3.69%)
88.63M

Discussion

View Full Feed
Zardiw Zardiw 3 minutes ago
Pls delete that post........and then this one.....

Z
Mattordaddy Mattordaddy 4 minutes ago
Yes with a b

https://investorshub.advfn.com/uimage/uploads/2024/4/28/fvtdstruckingt.jpg
ECSL
Zardiw Zardiw 4 minutes ago
$IDGR - #DDAmanda Analysis

https://www.youtube.com/watch?v=jFdniMXvLZU

Z
IDGR
BADALI BADALI 4 minutes ago
.0003 is definitely due here
https://x.com/witoshynskymike/status/1784530581042212956?s=46&t=y7yrqIlNM3fsfWkjz_Q1IQ
HMBL
Zardiw Zardiw 4 minutes ago
Pls delete that post.....and then this one....

Z
Zardiw Zardiw 5 minutes ago
$IDGR - #DDAmanda Analysis

https://www.youtube.com/watch?v=jFdniMXvLZU

Z
IDGR
Zardiw Zardiw 6 minutes ago
$IDGR - #DDAmanda Analysis

https://www.youtube.com/watch?v=jFdniMXvLZU

Z
IDGR
janice shell janice shell 6 minutes ago
Which shot? The one in my post? That's the quiche. From a completely different recipe.
HippyTrades HippyTrades 6 minutes ago
Zero, Zip, Zulch
PSRU
Inquirig Inquirig 7 minutes ago
Also Luke Johnson. Who seems as trustworthy as gas station sushi

https://x.com/MrLukeJohnston/status/1783937829363429646



JMHO
NWBO
janice shell janice shell 7 minutes ago
I guess Kristi couldn't be bothered to have it done.
Zorax Zorax 8 minutes ago
She did stir in the cheese. And the dough which was wrapped made little cinni bun look to them. What she pulled out is exactly what it would look like most likely. You can count the dough caps.

And the below shot is not from her unless she hired a pro product photographer, so don't kn
Benwahsauce Benwahsauce 9 minutes ago
Ty sir and appreciate the compliment!

I truly do this to help others and help educate. Inspite of most of IHUB…there are some very talented traders on this platform.

Some… are on completely different level
AMPUSD
Viking61 Viking61 10 minutes ago
New CNN poll, voters polled Trump 49% Biden 43%. This should bode well for us shareholders!! Whether you like Trump or not. GLTA!!
FNMA
arizona1 arizona1 10 minutes ago
Perhaps if she'd been around 20 years earlier, she could have castrated the goat, and he wouldn't have had to die.

Even I know that's what you need to do with an aggressive goat.
lakers17 lakers17 11 minutes ago
George Sharp has done squat. At this point he's a scammer. Has proved nothing. Still holding freebies here but almost worthless. He has lost all credibility.
GVSI
Inquirig Inquirig 11 minutes ago
Cool...
I'm in awe of your ability to be smarter and 5 steps ahead of all the smartest investors in the world who are stuck in the shabby world of buying Nasdaq and NYSE companies with promise, assets, more than 22 employees, institutional backing and marketable products - with competent CEOs
NWBO
LovePennyStock LovePennyStock 11 minutes ago
IMHO, the merger news(in 8-Ks) and filings(10-Qs, 10-Ks)should come all together. It doesn't make sense if you only release merger news or financing package news, but no filings you still in expert market and most of our share holders still can't trade. Or if they only file the past due 10-Qs, 10-Ks
PSPW
 just Scottie just Scottie 12 minutes ago
Also think it’s gonna require more patience than A lot of otc pink traders have
FBEC
janice shell janice shell 12 minutes ago
Quiche is okay. One of those things with eggs that I WILL eat. I should think about it. Maybe.
archilles archilles 13 minutes ago
Charles was with BGEN which was sold off to SAGA. Since Charles took the IPs from BGEN and found another bio company under his name, SAGA figured that BGEN was no longer valueable for them and SAGA decided to return BGEN.
We probably won’t be hearing from SAGA or ENZC on this question for an
ENZC
 just Scottie just Scottie 14 minutes ago
Yes me too!
FBEC
Box Money Box Money 14 minutes ago
Really?… after all this.. read something .. smh
LEAS

Your Recent History

Delayed Upgrade Clock